Optimizing smoking cessation pharmacotherapy and counseling for adult primary care patients: a factorial randomized controlled trial
Addictive Behaviors · 2026
DOI: 10.1016/j.addbeh.2026.108828 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Addictive Behaviors, 2026. Verfasst von Megan E Piper und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, USA; Center fo…. Hauptthemen laut MEDLINE: Smoking Cessation, Varenicline, Counseling, Smoking Cessation Agents. Die Arbeit nennt 27 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute, National Cancer Institute Division of Cancer Prevention.
Abstract (Originalsprache)
BACKGROUND: Even with the most effective smoking cessation pharmacotherapies (i.e., varenicline or combination nicotine replacement [C-NRT]), the majority of people ultimately return to smoking. This research explored how to optimize the use of varenicline and C-NRT to promote smoking cessation. METHODS: Primary care patients participated in a 2x2x2x2 factorial experiment that evaluated 4 factors: 1) Medication Type (Varenicline vs. C-NRT [patch + mini-lozenge]), 2) Preparation (pre-quit) Medication (4 Weeks vs. Standard); 3) Medication Duration (Extended [24 weeks] vs. Standard [12 weeks]); and 4) Counseling Type (Cessation Counseling [4 sessions] vs. Referral Support [2 sessions focused on use of referral resources]). This study was discontinued prior to reaching the proposed sample size (N = 608) due to pandemic-related budgetary constraints. RESULTS: Participants (N = 496) were 55% women and 45.6% Black individuals. There were no statistically significant main effects of the 4 factors on abstinence at 12, 26 or 52 weeks. There was a 3-way interaction between Medication Type, Preparation Medication, and Counseling Type (p = 0.04) predicting the primary outcome of biochemically confirmed abstinence at 52 weeks; cessation counseling vs. referral support improved varenicline quit rates when 4 weeks versus 1 week of pre-quit medication was offered. For C-NRT, counseling type did not significantly improve quit rates regardless of the use of preparation medication. CONCLUSIONS: There was no robust evidence that enhanced pre-quit or extended duration of varenicline or C-NRT increased abstinence rates. More intensive counseling may support cessation for different pharmacotherapy regimens. Given the lack of consistent findings, this research should be viewed as exploratory to guide future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of General Internal Medicine, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, USA; Center for Tobacco Research and Intervention, University of Wisconsin, Madison,…
- Center for Tobacco Research and Intervention, University of Wisconsin, Madison, USA.
- Department of Educational Psychology, University of Wisconsin, Madison, USA.
- Center for Tobacco Research and Intervention, University of Wisconsin, Madison, USA; Department of Kinesiology, University of Wisconsin, Madison, USA.
- Department of Social & Behavioral Sciences, School of Global Public Health, New York University, USA.
- Institute for Health Research and Policy, University of Illinois, Chicago, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Cancer Institute Division of Cancer Prevention
Zitieren
APA
Piper, M. E., Cook, J. W., McCarthy, D. M., Piasecki, T. M., Johnson, A. L., Bolt, D. M., Schlam, T. R., Collins, L. M., Mermelstein, R., Mundt, M. P., Kathuria, H., Fiore, M. C., & Baker, T. B. (2026). Optimizing smoking cessation pharmacotherapy and counseling for adult primary care patients: a factorial randomized controlled trial. Addictive Behaviors. https://doi.org/10.1016/j.addbeh.2026.108828
Vancouver
Piper ME, Cook JW, McCarthy DM, Piasecki TM, Johnson AL, Bolt DM, et al. Optimizing smoking cessation pharmacotherapy and counseling for adult primary care patients: a factorial randomized controlled trial. Addictive Behaviors. 2026. doi:10.1016/j.addbeh.2026.108828
BibTeX
@article{Piper2026,
author = {Piper, Megan E and Cook, Jessica W and McCarthy, Danielle M and Piasecki, Thomas M and Johnson, Adrienne L and Bolt, Daniel M and Schlam, Tanya R and Collins, Linda M and Mermelstein, Robin and Mundt, Marlon P and Kathuria, Hasmeena and Fiore, Michael C and Baker, Timothy B},
title = {Optimizing smoking cessation pharmacotherapy and counseling for adult primary care patients: a factorial randomized controlled trial},
journal = {Addictive Behaviors},
year = {2026},
doi = {10.1016/j.addbeh.2026.108828}
}
EUVIMED